News Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update Continue Reading Previous Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™Next Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program Related Stories News Interact Direct Holdings Limited Files Late Early Warning Report News Universal Digital Acquires 10 Bitcoin in First Treasury Allocation News Gorilla Provides Business Updates News SuperBuzz Announces Shares for Debt Offering News ISS Recommends Sonim Technologies Stockholders to Vote “FOR” Company Nominees on the WHITE Proxy Card News DesignRush Podcast #97: 5 Strategies to Turn Business Culture Into a Scaling Superpower from Top New York PR Agency
